<DOC>
	<DOCNO>NCT02444793</DOCNO>
	<brief_summary>This study Phase 1b , open label , multi center , multi-dose trial design estimate maximum tolerate dose ( MTD ) select recommend dose phase 2 ( RP2D ) investigations PF- 05082566 combination KW-0761 ( mogamulizumab ) patient advance solid tumor . Once MTD PF-05082566 administer combination KW-0761 estimate ( dose finding ) , one expansion cohorts patient select advanced solid tumor ( dose-expansion ) enrol characterize combination term safety profile , anti tumor activity , pharmacokinetics , pharmacodynamics biomarkers modulation .</brief_summary>
	<brief_title>A Study PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Histological cytological diagnosis advanced/metastatic solid tumor malignancy . Dose Finding Cohorts : Tumor type limit CRC , SCCHN , squamous NSCLC , bladder , ovarian carcinoma progress standard therapy , standard therapy available . Measurable disease RECIST version 1.1 . For Expansion Cohorts : patient must tumor accessible biopsy ( core needle biopsy excision prefer ) . Age 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate bone marrow , renal liver function . Serum/urine pregnancy test ( female childbearing potential ) negative screen patient receive study treatment . Male female patient childbearing potential risk pregnancy must agree use two ( 2 ) highly effective method contraception throughout study 60 day last dose assign study treatment . Active central nervous system primary secondary malignancy , active seizure disorder , spinal cord compression , carcinomatous meningitis . Therapeutic experimental monoclonal antibody last 60 day prior registration . Systemic anticancer therapy major surgery within 28 day prior registration . In absence toxicity prior systemic anticancer therapy , 5 halflives since completion prior systemic anticancer therapy allow . Systemic steroid , form immunosuppressive therapy radiation therapy within 14 day prior registration . Live vaccine within 30 day prior registration . Severe hypersensitivity reaction treatment another monoclonal antibody , know suspected hypersensitivity study drug component formulation . History autoimmune disease know inflammatory bowel disease . Uncontrolled hypertension ( blood pressure &gt; 150/100 mmHg despite optimal medical therapy ) follow within 12 month prior registration : myocardial infarction , congenital long QT syndrome , torsade de point , arrhythmia , right bundle branch block leave anterior hemiblock uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , ongoing NCICTCAE Grade 2 cardiac dysrhythmias , atrial fibrillation QTcF interval &gt; 470 msec .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>